

HOXC6 promotes migration, invasion and proliferation of esophageal squamous cell carcinoma cells via modulating expression of genes involved in malignant phenotypes

Li Tang, Yong Cao, Xueqin Song, Xiaoyan Wang, Yan Li, Minglan Yu, Mingying Li, Xu Liu, Fang Huang, Feng Chen and Haisu Wan

Experimental Medicine Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China

ABSTRACT

Background: *HOXC6* is a member of the *HOX* gene family. The elevated expression of this gene occurs in prostate and breast cancers. However, the role of *HOXC6* in esophageal squamous cell carcinoma (ESCC) remains largely uninvestigated.

Methods: The expression of *HOXC6* was examined by immunohistochemistry, quantitative real-time PCR and immunoblotting assays. The lentivirus-mediated expression of *HOXC6* was verified at mRNA and protein levels. Wound healing and Matrigel assays were performed to assess the effect of *HOXC6* on the migration and invasion of cancer cells. The growth curving, CCK8, and colony formation assays were utilized to access the proliferation capacities. RNA-seq was performed to evaluate the downstream targets of *HOXC6*. Bioinformatic tool was used to analyze the gene expression.

Results: *HOXC6* was highly expressed in ESCC tissues. *HOXC6* overexpression promoted the migration, invasion, and proliferation of both Eca109 and TE10 cells. There were 2,155 up-regulated and 759 down-regulated genes in Eca109-*HOXC6* cells and 95 up-regulated and 47 down-regulated genes in TE10-*HOXC6* cells compared with the results of control. Interestingly, there were only 20 common genes, including 17 up-regulated and three down-regulated genes with similar changes upon *HOXC6* transfection in both cell lines. *HOXC6* activated several crucial genes implicated in the malignant phenotype of cancer cells.

Discussion: *HOXC6* is highly expressed in ESCC and promotes malignant phenotype of ESCC cells. *HOXC6* can be used as a new therapeutic target of ESCC.

Subjects Cell Biology, Molecular Biology, Oncology

Keywords ESCC, Homeobox, *HOXC6*, Migration, Invasion, Proliferation

INTRODUCTION

Esophageal squamous cell carcinoma (ESCC) incidence is the eighth highest, and mortality is the sixth highest, of all cancers worldwide (Cai *et al.*, 2015). Despite the fact that many efforts have been made to improve the diagnosis and therapy of ESCC, the overall

Submitted 2 November 2018

Accepted 10 February 2019

Published 14 March 2019

Corresponding author

Haisu Wan, whssyzx@swnu.edu.cn

Academic editor

Shi-Cong Tao

Additional Information and
Declarations can be found on
page 17

DOI 10.7717/peerj.6607

© Copyright

2019 Tang et al.

Distributed under

Creative Commons CC-BY 4.0

OPEN ACCESS

5-year survival rate remains disappointing, and it is still one of the most fatal malignancies (Kashyap *et al.*, 2009; Zhang, 2013). The main reason for this is that ESCC is usually in the advanced stages at diagnosis (Kashyap *et al.*, 2009; Zhang, 2013). To address this problem, it is necessary to identify potential molecular markers that may be used for the diagnosis and therapy of ESCC.

Homeobox-containing gene family comprises approximately 200 transcription factors which share a 183 base pairs long DNA region called homeobox in their coding sequences, and the homeobox encodes a 61 amino acids homeodomain (HD) with characteristic fold (Cantile *et al.*, 2011). The *HOX* genes are a subgroup of homeobox-containing genes encoding transcription factors that confer segmental identities in the process of development. In humans, there are 39 *HOX* genes clustered into four different groups (*HOXA*, *HOXB*, *HOXC*, and *HOXD*). *HOX* genes are crucial to the regulation and control of the processes important to development, such as receptor signaling, apoptosis, motility, differentiation, and angiogenesis (Zhang *et al.*, 2013). Many *HOX* genes have been found to be either activated or repressed in the process of cancer development. Aberrant expression of *HOX* genes has also been reported in a variety of cancers, such as colorectal (Kanai *et al.*, 2010; Liao *et al.*, 2011), breast (Hur *et al.*, 2014; Shaoqiang *et al.*, 2013), prostate (Chen *et al.*, 2012b), glioblastoma (Costa *et al.*, 2010), and lung (Abe *et al.*, 2006) cancers.

HOXC6 is a member of the *HOX* family, and its aberrant expression has been verified in a variety of cancers, such as prostate (Ramachandran *et al.*, 2005), breast (Hussain *et al.*, 2015), nasopharyngeal carcinoma (Chang *et al.*, 2017), gastric (Zhang *et al.*, 2013), and ovarian (Tait *et al.*, 2015) cancers. *HOXC6* overexpression promoted cell migration, invasion and proliferation, where decreased *HOXC6* expression reversed the facilitation effect on gastric cancer cells (Chen *et al.*, 2016). In hepatocellular carcinoma, *HOXC6* overexpression promoted cell proliferation, while siRNA-mediated *HOXC6* down-regulation not only inhibited proliferation and migration but also increased 5-FU chemosensitivity (Sui *et al.*, 2016). Ji *et al.* (2016) also found that silencing of *HOXC6* expression inhibited the proliferation of colorectal cancer cells. Collectively, these studies suggest that *HOXC6* might be involved in tumor initiation and progression. In the case of ESCC, it is predicated that *HOXC6* may be highly expressed in ESCC tissues compared to adjacent normal counterparts (Du *et al.*, 2014). However, the role of *HOXC6* in ESCC has not been fully investigated. Here, we report that *HOXC6* functions as an oncogene in ESCC cells via up-regulation of genes associated with the malignant phenotype. *HOXC6* is a candidate molecular marker for both the diagnosis and treatment of ESCC.

MATERIALS AND METHODS

Cell lines and cell culture

The ESCC cell lines, Eca109 and TE10, were purchased from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). 293FT cell line was obtained from Shanghai Tongpai biotechnology co. LTD (Shanghai, China). Eca109 and TE10 cells were cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) and 293FT cells was maintained in DMEM (Gibco, Grand Island, NY, USA). All mediums were supplemented

with 10% fetal bovine serum (Gibco, Grand Island, NY, USA), 100 μ /ml of penicillin and 100 μ /ml of streptomycin. All cells were cultured in a 37 °C, 5% CO₂ incubator.

Patients and specimens

Esophageal squamous cell carcinoma tissues and adjacent normal counterpart specimens were obtained from patients with ESCC who were treated with surgery between January 2017 and August 2017 at the Department of Thoracic Surgery, the Affiliated Hospital of Southwest Medical University (Luzhou, China). A portion of each specimen was immediately frozen in liquid nitrogen for qRT-PCR and western blotting assays. Another portion was immediately fixed in neutral formalin buffer and embedded into paraffin for histopathological observation. The present study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University (NO. K2018002-R). Written informed consents for this study were obtained from all patients.

RNA extraction and qRT-PCR

Total RNA from cells and tissues was extracted with Trizol (Invitrogen, Carlsbad, CA, USA; Thermo Fisher Scientific Inc., Waltham, MA, USA) following the manufacturer's instructions. For each specimen, 500 ng of total RNA was used for reverse-transcription using the PrimeScriptTMRT reagent Kit with gDNA Eraser (TaKaRa Bio Inc., Tokyo, Japan). The reaction conditions of reverse-transcription were 15 min at 37 °C, and 5 s at 85 °C. qRT-PCR examination was performed using SYBR Premix Ex Taq II (Tli RNaseH Plus) (TaKaRa Bio Inc., Tokyo, Japan). The primer sequences are shown in [Table 1](#). The reaction conditions were as follows: 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s, then 60 °C for 34 s. Reactions were carried out in an Applied Biosystems 7500 Real Time PCR System (Applied Biosystems, Foster City, CA, USA; Thermo Fisher Scientific Inc., Waltham, MA, USA). The expression of *GAPDH* was used as an internal control and the RNA expression level of each gene was evaluated using the $2^{-\Delta\Delta ct}$ method. All specimens were examined in triplicate.

Immunohistochemistry

Formalin-fixed paraffin-embedded blocks were prepared into tissue sections. The sections were treated with 3% H₂O₂ for 10 min after routine deparaffinization in xylene and rehydration in decreasing concentrations of ethanol (100, 95, 85, and 75%). Then, sections were heated in citrate sodium for approximately 3 min for antigen retrieval. To block nonspecific reactions, the sections were incubated with 10% normal goat serum for 20 min after antigen retrieval. Then, the sections were incubated with a mouse monoclonal antibody against human *HOXC6* (Santa Cruz, dilution, 1:200) overnight at 4 °C. After primary antibody incubation, the streptavidin/peroxidase amplification kit (ZSGB-Bio, Beijing, China) was used for the *HOXC6* antigen-antibody reaction. Then, sections were treated with diaminobenzidine to visualize the appearance of *HOXC6* signal. To quantitate the expression of *HOXC6*, two specialists in pathology independently scored the immunohistochemical signals according to intensity (0–3) and extent (0–100%). The staining intensity was categorized as follows: 0, negative (–); 1, weak (+); 2, moderate (++);

Table 1 The primer sequences for qRT-PCR.

Gene	Primer sequence (5'-3')	
	Forward	Reverse
HOXC6	ACAGACCTCAATCGCTCAGGA	AGGGGTAAATCTGGATACTGGC
MMP14	CGAGGTGCCCTATGCCTAC	CTCGGCAGAGTCAAAGTGG
SPARC	AGCACCCCATTGACGGGTA	GGTCACAGGTCTCGAAAAAGC
FN1	CGGTGGCTGTCAGTCAAAG	AAACCTCGGCTTCTCCATAA
INHBA	CAACAGGACCAGGACCAAAGT	GAGAGCAACAGTTCACCTCCTC
SEMA3C	TAACCAAGAGGAATGCGGTCA	TGCTCCTGTTATTGTCAGTCAGT
HEY1	ATCTGCTAAGCTAGAAAAAGCCG	GTGCGCGTCAAAGTAAACCT
SGK1	GCAGAAGAAGTGTCTATGCAGT	CCGCTCCGACATAATATGCTT
SMAD9	CTGTGCTCGTGCCAAGACA	TGAAAAGAGTCAGGATAGGTGG
WNT6	GGTGGAGAGTGCCAGTTC	CGTCTCCCGAATGTCTGT
BRCA2	CACCCACCCTTAGTTCTACTGT	CCAATGTGGTCTTTGCAGCTAT
SAMD9	GCAACCATCCATAGACCTGAC	AATAGTGCCATTGGTACGTGAAT
AKAP9	CACGGCATAAGGGAGAAATGG	GCTGTCTCTGTAGAGCACACT
SATB1	CCAGGTTGAAAGTGAATCC	GGGGCAACTGTGTAAGTGAAT
CFH	GTGAAGTGTTTACCAGTGACAGC	AACCGTACTGCTTGTCCAAAA
JAK2	TCTGGGGAGTATGTTGCAGAA	AGACATGGTTGGGTGGATACC
MCTP1	AGTTTACGCCTATCAGACCTACA	GATCGCTCAACCCGTTGGAAT
ANXA10	GCTGGCCTCATGTACCCAC	CAAGCAGTAGGCTTCTCGC
DAPP1	CAGCCTTGATTGGAAGCGAG	TGTGAACCCGGACAGATTTCAT
GAPDH	CTCTGACTTCAACAGCGACACC	CTGTTGCTGTAGCCAAATTCGTT

and 3, strong (+++). The expression of *HOXC6* was calculated as the product of the intensity and extent scores (IHC score).

Western blotting

Lysates of cells and tissues were prepared using pre-cooled RIPA buffer (Cell Signaling, Danvers, MA, USA) supplemented with proteinase inhibitor (Roche, Indianapolis, IN, USA). The total protein concentration was tested using the BCA protein assay kit (Thermo Fisher Scientific Inc., Waltham, MA, USA). Total protein lysate (20 µg) of each sample was separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, USA). Next, the membranes were soaked in 5% skim milk powder to block nonspecific reactions and then incubated with mouse monoclonal antibody against human *HOXC6* (Santacruz, dilution, 1:1,000) overnight at 4 °C. Membranes were then incubated with the corresponding secondary antibody for 30 min. Immunoreactive protein was visualized using the Western Lighting Chemiluminescence Reagent Plus (PerkinElmer, Waltham, CA, USA). β-actin (Santacruz, dilution, 1:1,000) was used as internal control.

Establishment of cell lines stably expressing the exogenous *HOXC6*

The lentiviral *HOXC6*-expression vector pCDH-*HOXC6* was constructed by cloning the human *HOXC6* gene into pCDH-NEO vector which is generated by replacing the

Table 2 The primer sequences for PCR amplification.

Gene fragment	Primer sequence (5'-3')
PCDH-CMV-MCS-EF1	Forward GCGTGGATATCTAAGTCGACAATCAACCTCTGG
	Reverse AATATCTCGAGGGTGGCGTCTAGCGTAGGCG
Genemycin resistance gene	Forward GTCTACTCGAGGCCACCATGATTGAACAAGATGGATTGCAC
	Reverse GCTATGATATCTCAGAAGAAGCTCGTCAAGAAGGC
HOXC6	Forward CCCGGTCTAGAGCCACCATGAATTCCTACTTCACTAACCCCTTCC
	Reverse TTGGCGGATCCTCACTCTTCTGCTTCTCCTCTTC

copGFP gene with genemycin resistance gene of pCDH-CMV-MCS-EF1-copGFP (JiRan, Shanghai, China). The primer sequences including the XhoI and EcoRV restriction enzyme sites are shown in Table 2. The lentiviral particles were produced by transfecting either pCDH-HOXC6 or pCDH-NEO with psPAX2 and pMD2.G into 293FT cells. The culture supernatant was harvested and subsequently infected Eca109 and TE10 cells. The stable cells were selected by genemycin at a concentration of 500 µg/ml (Thermo Fisher Scientific Inc., Waltham, MA, USA).

Wound healing and matrigel invasion assay

Cells were seeded in 96-well plates and allowed to achieve 90–100% confluence. The Essen Bioscience 96-pin wound maker (Essen BioScience, Ann Arbor, MI, USA) was used to create a uniform scratch in each well. For the wound healing assay, cells were incubated in RPMI 1640 medium supplemented with 2% fetal bovine serum. For the invasion assay, cells were covered with 50 µl of Matrigel solution (2.4 mg/ml Matrigel in normal growth medium, BD Biosciences, San Jose, CA, USA) that was allowed to gel at 37 °C for 1 h. Then, an additional 100 µl/well of normal growth medium was used to overlay the matrix. The wound of each well was monitored and images were taken at 2 h intervals in an IncuCyte live-cell analysis system (Essen BioScience, Ann Arbor, MI, USA). The wound width was calculated using the software provided.

Growth, CCK8, and colony formation assays

Cells were plated in 96-well plates (3,000 cells/well). Cell growth was monitored and images were taken at 2 h intervals in an IncuCyte live-cell analysis system. Growth curves were calculated from confluence measurements using image analysis software. For the Cell Counting Kit-8 assay (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), optical density was measured to determine cell activity at a wavelength of 450 nm on a microplate reader at 0, 24, 48, and 72 h. For the colony formation assay, stably infected cells were seeded in six-well plates (200 cells/well) and the growth medium was changed at 3-day intervals. After 10 days of incubation at 37 °C with 5% CO₂, cells were fixed with 4% paraformaldehyde and stained with freshly prepared, diluted Giemsa stain for 20 min. Colony number was counted after excess dye was washed off with double-distilled water.

RNA-seq analysis

Total RNA was isolated with Trizol and the polyadenylated mRNAs were enriched using Dynabeads Oligo (dT) 25 beads. Three replicates were created for RNA-seq library construction using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB, Ipswich, MA, USA), following the manufacturer's instructions. Illumina HiSeq Xten was used to perform 150 bp pair-end sequencing. We mapped all RNA-seq data to the GRCh37.p13 genome from GENCODE (Harrow *et al.*, 2012) by HISAT2 (version 2.1.0) (Kim, Langmead & Salzberg, 2015) with default parameters. To identify differentially expressed genes (DEGs), we aggregated the read counts at the gene level using HTseq (Anders, Pyl & Huber, 2015), and then identified DEGs using R package DESeq2 (Love, Huber & Anders, 2014). Genes were considered significantly differentially expressed when the $|\log_2(\text{fold-change})| > 1$ and adjusted $p < 0.05$. DEGs were subjected to enriched GO categorization using the R package clusterProfiler (Yu *et al.*, 2012) with a q -value < 0.05 .

Bioinformatic analysis

Gene Expression Omnibus (GEO) is a public functional genomics data repository supporting MIAME-compliant data submissions. We utilized this tool to investigate gene expression. GEO is available at <https://www.ncbi.nlm.nih.gov/geo/>.

Statistical analysis

All experimental data are presented as the mean \pm standard deviation from two to three separate experiments. Wound healing Matrigel invasion and growth curve assays were conducted in at least 12 repeats for every separate experiment. CCK8 and colony formation assays were conducted in triplicate. Data was analyzed using SPSS19.0 software. Comparisons between groups were performed using Student's t -test, and differences were considered statistically significant at $p < 0.05$.

RESULTS

HOXC6 was highly expressed in ESCC tissues

HOXC6 is highly expressed in many cancer types (Figs. 1A–1I), including ESCC (Figs. 1G–1I). This suggests that *HOXC6* may be a critical factor in cancer development. However, the role of this gene in ESCC is not clear. We investigated the expression of *HOXC6* in ESCC cells. We first investigated the expression of *HOXC6* using clinical tumor samples. A total of 32 paired samples from patients that underwent ESCC resection were used to verify the expression of *HOXC6* by IHC and qRT-PCR. Representative images of the *HOXC6* IHC assays are shown in Fig. 2A. The IHC score of *HOXC6* in tumor tissues was significantly higher than in adjacent normal counterparts (Fig. 2B). The relative *HOXC6* mRNA expression level in tumor tissues was also significantly higher than in adjacent normal counterparts (Fig. 2C). We randomly selected three paired samples to analyze the expression level of the *HOXC6* protein by western blotting, and the results showed that *HOXC6* in tumor tissues was highly expressed when compared with adjacent normal counterparts (Figs. 2D and 2E). These results suggest that *HOXC6* expression may play a role in the malignancy of ESCC.




Figure 1 *HOXC6* is highly expressed in many cancer types. Microarray data retrieved from gene expression omnibus (GEO) repository were utilized to analyze *HOXC6* expression at mRNA level in various cancers including (A) lung cancer, (B) colorectal cancer, (C) prostate cancer, (D) soft-tissue sarcoma, (E) renal carcinoma, (F) gastric cancer and (G-I) ESCC.

Full-size DOI: 10.7717/peerj.6607/fig-1

HOXC6 promoted ESCC cell migration and invasion

To explore how *HOXC6* affects the malignant phenotype of ESCC cells, we introduced the *HOXC6* gene into Eca109 and TE-10 cells via lentiviral-mediated transfection, generating cell lines stably expressing *HOXC6* (Eca109-*HOXC6* and TE10-*HOXC6*) as well as cell lines transfected with empty vector (Eca109-NEO and TE10-NEO). Fig. 3A shows the lentiviral vector pCDH-*HOXC6*. The expression level of *HOXC6* was confirmed by both qRT-PCR (Fig. 3B), western blotting (Figs. 3C and 3D) and immunocytochemistry assay (Fig. 3E). Since the migration and invasion of tumor cells is critical for tumor angiogenesis and metastasis, we assessed the effect of *HOXC6* on ESCC cell migration and invasion using wound healing and Matrigel invasion assays. By calculating wound healing width and invasion width of the scratch wound, we found that *HOXC6* overexpression significantly increased cell migration speed in Eca109-*HOXC6* and TE10-*HOXC6* cells




Figure 2 HOXC6 was highly expressed in ESCC tumor tissues. (A) Representative images and (B) IHC score of HOXC6 from immunohistochemical analysis. (C) Relative *HOXC6* mRNA expression levels in tumor tissues compared with normal tissues as measured by qRT-PCR. Each of the columns in the bar graph represents the value of one tumor sample as compared with that of its normal control. The expression of *GAPDH* was used as the internal control. HOXC6 mRNA expression level was evaluated using the $2^{-\Delta\Delta ct}$ method. All specimens ($n = 32$) were examined in triplicate. (D) Representative images of western blot, β -actin has been used as an internal control. (E) The quantification of the relative expression level of HOXC6 as determined by normalized gray values. ** $p < 0.01$; *** $p < 0.001$. [Full-size !\[\]\(5fd6ef84f97f42d7f8b34275f1b65312_img.jpg\) DOI: 10.7717/peerj.6607/fig-2](https://doi.org/10.7717/peerj.6607/fig-2)

compared to controls (Figs. 4A–4F). The Matrigel invasion assay demonstrated that *HOXC6* significantly improved the invasive capacity of the ESCC cells (Figs. 5A–5F). These results suggest that *HOXC6* may act as a facilitator in promoting ESCC cell migration and invasion.

HOXC6 promoted ESCC cell proliferation

To assess the effect of *HOXC6* on ESCC cell proliferation, we utilized a real-time monitoring assay to measure the growth rates of Eca109-HOXC6 and TE10-HOXC6 as well as their controls. Growth curves were constructed from data points acquired at 2 h intervals. Results showed that the growth of Eca109-HOXC6 and TE10-HOXC6 was significantly faster than that of controls (Figs. 6A and 6B). Furthermore, CCK8 and colony formation assays were also performed. The OD450 values of Eca109-HOXC6 and TE10-HOXC6 were higher than that of controls when measured after 72 h




Figure 3 Lentiviral vector and verification of HOXC6 overexpression. (A) The recombinant lentiviral vector pCDH-HOXC6. (B) The quantification of relative *HOXC6* mRNA expression levels as measured by qRT-PCR. *GAPDH* has been used as the internal control. (C) The result of western blot and (D) the quantification of relative HOXC6 protein expression levels as determined by the normalized gray values. β-actin has been used as an internal control. (E) HOXC6 expression in HOXC6-transfected cells and their controls examined by immunocytochemical staining. ** $p < 0.01$; *** $p < 0.001$.

Full-size DOI: 10.7717/peerj.6607/fig-3

(Figs. 6C and 6D). In addition, the results of the colony formation assay showed that Eca109-HOXC6 and TE10-HOXC6 generated more colonies than the controls (Figs. 6E–6H). Collectively, these results suggest that *HOXC6* may increase the proliferation and colony formation of ESCC cells.

RNA-seq analysis identified genes regulated by *HOXC6*

As a member of the homeobox gene family, *HOXC6* possesses the characteristics of a transcription factor that can bind to a specific sequence in the genome and regulate the expression of related genes. To identify the downstream targets and the regulatory network of *HOXC6*, RNA-seq was conducted to compare changes of mRNA expression patterns following *HOXC6* transfection. The raw RNA-seq data in this article has been uploaded to GEO repository and the accession number is GSE121976. The expression levels of individual genes were measured by sequence counts. Genes with at least a two-fold change




Figure 4 *HOXC6* promoted ESCC cell migration. Wound healing assay was performed to evaluate the migration of stably infected cells. Representative images from the wound healing assay in (A) Eca109 and (B) TE10 stable cells. (C–D) The wound healing width of Eca109-HOXC6 was significantly wider than in the Eca109-NEO cells. Similarly, (E–F) the effect of HOXC6 expression on the ability of wound healing of the two ESCC cell lines. There were at least 12 replicates included for each cell line. These data demonstrated that *HOXC6* promoted ESCC cell migration. *** $p < 0.001$. [Full-size !\[\]\(52516a3edab5b871bdd69195863186f9_img.jpg\) DOI: 10.7717/peerj.6607/fig-4](https://doi.org/10.7717/peerj.6607/fig-4)

in expression were viewed as either up-regulated or down-regulated genes. The global changes in mRNA expression patterns are shown in Fig. 7A and 7B for Eca109-HOXC6 and TE10-HOXC6. As shown in Fig. 7C and 7D, there were 2,155 up-regulated and 759 down-regulated genes in Eca109-HOXC6 cells compared with Eca109-NEO cells. In addition, there were 95 up-regulated and 47 down-regulated genes in TE10-HOXC6 cells compared with TE10-neo cells. Interestingly, there were only 20 common genes, including 17 up-regulated and three down-regulated genes with similar changes upon *HOXC6* transfection in both cell lines indicating the cell-context dependent function of *HOXC6* in different cell lines. The common regulated genes are shown in Fig. 7E in the format of a table. There are 14 common up-regulated genes, many of these genes have been reported to be implicated in the development of various types of cancers. There are also three common down-regulated genes, however, the function of these genes has not been




Figure 5 *HOXC6* promoted ESCC cell invasion. Matrigel invasion assay was used to assess cell invasion capacity. Representative images from the Matrigel invasion assay in (A) Eca109 and (B) TE10 stable cells. By calculating the invasion width, the invasion capacity of (C–D) Eca109-HOXC6 and (E–F) TE10-HOXC6 cells was greater than the controls. These data demonstrate that *HOXC6* effectively promoted ESCC cell invasion. * $p < 0.05$; ** $p < 0.01$. Full-size [DOI: 10.7717/peerj.6607/fig-5](https://doi.org/10.7717/peerj.6607/fig-5)

well characterized. We further confirmed the results of RNA-seq by examining the expression of *HOXC6*-modulated genes using qRT-PCR. As shown in Figs. 7F and 7G, changes in expression level of these genes were consistent with the RNA-seq results.

***HOXC6* up-regulated critical genes involved in malignant phenotype**

To understand the mechanism underlying the function of *HOXC6*, we investigated the downstream targets identified by RNA-seq. As demonstrated by GO analysis (Figs. 7H and 7I), the genes regulated by *HOXC6* could be categorized into various functional groups, including organelle fission and nuclear division in Eca109-HOXC6 cells, and angiogenesis and tRNA aminoacylation for protein translation in TE10-HOXC6 cells. Functional pathway analysis (Figs. 7J and 7K) suggested that *HOXC6* may have functions mediated by crosstalk with important signaling pathways such as p53 and focal adhesion in




Figure 6 *HOXC6* promoted ESCC cell proliferation. Growth curves were constructed via real-time monitoring. (A) The growth curve of Eca109-HOXC6 and Eca109-NEO cell lines. (B) The growth curve of TE10-HOXC6 and TE10-NEO cell lines. (C-D) The growth curves as determined by OD450 values using CCK8 kit and (E-H) colony formation assay was also used to evaluate the colony formation ability of these cell lines. CCK8 and colony formation assays were conducted in triplicate. Overall, these data suggest that *HOXC6* promoted ESCC cell proliferation. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Full-size DOI: [10.7717/peerj.6607/fig-6](https://doi.org/10.7717/peerj.6607/fig-6)




Figure 7 RNA-seq analysis of the interactive genes of *HOXC6* in Eca109 and TE10 stable cells. (A–B) The volcano diagrams show the global changes in mRNA expression patterns for Eca109 and TE10 stable cells. (C–D) The Venn diagrams show the common up-regulated genes and down-regulated genes and (E) the common regulated genes are also shown in the table. (F–G) The relative expression of genes regulated by *HOXC6* at the mRNA level were identified by qRT-PCR. (H–I) GO analysis showed various functional groups of genes regulated by *HOXC6* and (J–K) KEGG pathway analysis showed functional pathways for Eca109 and TE10 stable cells. Full-size [DOI: 10.7717/peerj.6607/fig-7](https://doi.org/10.7717/peerj.6607/fig-7)

Eca109-HOXC6 cells, and the TGF- β signaling pathway and aminoacyl-tRNA biosynthesis in TE10-HOXC6 cells. These analyses indicate that *HOXC6* executed its function via distinct mechanisms in various cell lines. However, these results failed to provide clear clues to how *HOXC6* affects the malignant phenotype of cells. We then investigated the genes up-regulated in both Eca109-HOXC6 and TE10-HOXC6 cells. Interestingly, as indicated in Table 3, there were many genes involved in the malignant phenotype of various cancers. Furthermore, as demonstrated by bioinformatic analysis (Fig. 8), some of the genes up-regulated by *HOXC6* were highly expressed in ESCC. In the present study, *HOXC6* further up-regulated the expression of these genes. This evidence suggests that *HOXC6* may execute its function via activating the expression of genes involved in malignant phenotype.

DISCUSSION

Tumor development is often associated with the abnormal expression of critical genes (Hanahan & Weinberg, 2011; Wang et al., 2013). *HOXC6* belongs to the *HOX* gene

Table 3 List of genes regulated by *HOXC6* in Eca109 and TE10 stable cells.

Gene	Description of function	Cancer type	Reference	
Eca109-up	MMP14	Promote cell migration and invasion	Nasopharyngeal carcinoma	<i>Yan et al. (2015)</i>
		Promote tumor invasion and angiogenesis	Pituitary adenomas	<i>Hui et al. (2015)</i>
	SATB1	Promote cell growth and invasion	pancreatic cancer	<i>Chen et al. (2015)</i>
		Promote cell growth and invasion	Prostate cancer	<i>Mao et al. (2013)</i>
		Promote cell invasion and metastasis	Breast cancer	<i>Han et al. (2008)</i>
	AKAP9	Promote proliferation, migration and invasion	Colorectal cancer	<i>Yang et al. (2015)</i>
		Promote proliferation, migration and invasion	Colorectal cancer	<i>Hu et al. (2016)</i>
	CFH	Promote proliferation and migration	Cutaneous squamous cell carcinoma	<i>Riihila et al. (2014)</i>
		Promote tumorsphere formation	Liver cancer	<i>Seol et al. (2016)</i>
	JAK2	JAK2 inhibition prevents cell migration and invasion	Glioblastoma	<i>Senft et al. (2011)</i>
JAK2 inhibition suppresses cell migration, invasion and proliferation		Cervical cancer	<i>Luo et al. (2016)</i>	
TE10-up	SPARC	Promote cell invasion and growth	Gastric cancer	<i>Yin et al. (2010)</i>
		Promote cell proliferation, invasion and metastasis, induced cell apoptosis	Ovarian cancer	<i>Chen et al. (2012a)</i>
	FN1	Promote proliferation, migration and invasion	Thyroid cancer	<i>Sponziello et al. (2016)</i>
		Promote proliferation, migration and invasion	Gastric cancer	<i>Zhang et al. (2017)</i>
	WNT6	Promote proliferation, cell cycle and migration, but inhibit cell apoptosis	Colon cancer	<i>Zheng & Yu (2018)</i>
		Inhibit cell apoptosis	Gastric cancer	<i>Yuan et al. (2013)</i>
Common-up	SEMA3C	Promote tumor growth and metastasis	Pancreatic ductal adenocarcinoma	<i>Xu et al. (2017)</i>
		Promote the survival and tumorigenicity of glioma stem cells	Glioma	<i>Man et al. (2014)</i>
		Promote adhesion, invasion and proliferation	Breast cancer	<i>Malik et al. (2016)</i>
	INHBA	Promote cell proliferation	Lung adenocarcinoma	<i>Seder et al. (2009b)</i>
		Promote cell proliferation	Esophageal adenocarcinoma	<i>Seder et al. (2009a)</i>
	SGK1	Promote cell proliferation and migration	Colorectal cancer	<i>Liang et al. (2017)</i>
		Promote cell proliferation	Colorectal cancer	<i>Lang, Perrotti & Stournaras (2010)</i>
	HEY1	Promote cell invasion and metastasis	Osteosarcoma	<i>Tsuru et al. (2015)</i>
		Promote proliferation	Glioblastoma	<i>Hulleman et al. (2009)</i>

family and encodes HD-containing transcription factors with the capacity to bind specific DNA sequences and regulate the expression of downstream genes (*Hussain et al., 2015*). The aberrant expression of *HOXC6* has been reported in many cancer types; however, the mechanisms underlying the function of this gene in cancer cells have not been fully elucidated. We explored the role of *HOXC6* in the malignant phenotype of ESCC. Based on our results, the expression of *HOXC6* was significantly elevated in ESCC cells. In addition, ectopic expression of *HOXC6* promoted the migration, invasion, and proliferation of ESCC cells. Since these phenotypes are directly related to the development and progression of cancer, *HOXC6* emerges as an oncogene in ESCC. This is




Figure 8 Gene expression omnibus database analysis. Many genes regulated by *HOXC6* in ESCC such as (A–B) *MMP14*, (C–D) *SPARC*, (E–F) *FN1*, (G–H) *INHBA*, (I–J) *SEMA3C* and (K–L) *HEY1* were highly expressed in ESCC. [Full-size !\[\]\(ebfe6d37ad86655679811e032f633da4_img.jpg\) DOI: 10.7717/peerj.6607/fig-8](https://doi.org/10.7717/peerj.6607/fig-8)

consistent with the results of other reports focused on the function of *HOXC6* in cancers other than ESCC.

Like other HD proteins, *HOXC6* may execute its effects via binding to specific sequences in the genome following *HOXC6* transfection. However, to our surprise, we found that *HOXC6* exerted its effects on the transcription patterns of cancer in a cell-context-dependent manner. *HOXC6* modulated distinct sets of genes in different ESCC cell lines. This may result from the fact that the specificity of an HD protein usually requires the formation of various complexes, and the availability of other cofactors may be critical for the modulation of downstream targets (Ladam & Sagerstrom, 2014). Many factors have been identified as interacting partners of homeobox-containing gene products.

For example, these factors may interact with other members of the HD protein family, chromatin remodeling factors, or other transcription factors (*Ladam & Sagerstrom, 2014*). The function of an HD protein may be influenced by both the expression level and the modification status of these interacting partners.

To determine the mechanisms underlying the oncogenic function of *HOXC6*, we compared the genes that were up-regulated in Eca109-*HOXC6* and TE10-*HOXC6* cells. Results showed that both of these cell lines contain genes with unambiguous functions that are associated with the malignant phenotype in various types of cancers. These genes included *MMP14*, *SPARC*, and *FNI*. *MMP14* is a member of the matrix metalloproteinase (*MMP*) family, which can degrade collagen and other extracellular matrix proteins (*Ulasov et al., 2014*). *MMP14* not only promotes cell migration, invasion, and angiogenesis in nasopharyngeal carcinoma (*Yan et al., 2015*) and pituitary adenomas (*Hui et al., 2015*) but also promotes the secretion of pro-*MMP2* and pro-*MMP9* (*Zarrabi et al., 2011*). *SPARC* is a collagen-binding glycoprotein that interacts with *MMPs* and growth factors, such as TGF- β and fibroblast growth factor (*Vaz et al., 2015*). *SPARC* can enhance cell invasion, metastasis, and growth while inducing apoptosis in gastric (*Yin et al., 2010*) and ovarian (*Chen et al., 2012a*) cancers. *FNI* can induce abnormal expression of some *MMPs*, such as *MMP9/MMP2* (*Moroz et al., 2013; Qian et al., 2011*) and promote proliferation, migration, and invasion in thyroid (*Sponziello et al., 2016*) and gastric (*Zhang et al., 2017*) cancers. In addition, *AKAP9*, *SATB1*, *SEMA3C*, *SGK1*, and *INHBA*, etc. have also been reported to enhance cell migration, invasion, proliferation and angiogenesis or induce apoptosis in various cancers, such as pancreatic (*Chen et al., 2015; Xu et al., 2017*), glioma (*Hulleman et al., 2009; Man et al., 2014; Senft et al., 2011*), breast (*Han et al., 2008; Malik et al., 2016*), lung (*Seder et al., 2009b*), esophageal (*Seder et al., 2009a*), prostate (*Mao et al., 2013*), and colorectal (*Hu et al., 2016; Lang, Perrotti & Stourmaras, 2010; Liang et al., 2017; Yang et al., 2015; Zheng & Yu, 2018*), cutaneous squamous cell carcinoma (*Riihila et al., 2014*), liver (*Seol et al., 2016*), cervical (*Luo et al., 2016*), gastric (*Yuan et al., 2013*) and osteosarcoma (*Tsuru et al., 2015*) cancers.

In conclusion, *HOXC6* promoted ESCC cell migration, invasion, and proliferation, and its function may be related to the aberrant expression of genes caused by *HOXC6* overexpression. *HOXC6* may be a new significant biomarker for diagnosis, therapy, and prognosis. Targeted inhibition of *HOXC6* may be a new strategy for the treatment of ESCC. However, the precise molecular mechanism is not completely understood, and further investigation is still needed.

CONCLUSION

HOXC6 promoted the malignant phenotypes of ESCC cells. *HOXC6* could activate the expression of oncogenic genes in a cell context-dependent manner. Targeted inhibition of *HOXC6* might provide a new strategy for the therapy of ESCC.

ACKNOWLEDGEMENTS

We offer many thanks to all colleagues for their contribution to this study.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

This study was supported by the grants from the Joint Program on the Science and Technolog Collaboration of Southwest Medical University and the Government of Luzhou City (No. 2018LZXNYD-PT04), the Science Technology Support Plan Projects of Luzhou (No. 2015LZCYD-S02) and the Project Program of Southwest Medical University (2017-ZRQN-005). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

Joint Program on the Science and Technolog Collaboration of Southwest Medical University and the Government of Luzhou City: 2018LZXNYD-PT04.

Science Technology Support Plan Projects of Luzhou: 2015LZCYD-S02.

Project Program of Southwest Medical University: 2017-ZRQN-005.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Li Tang performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, authored or reviewed drafts of the paper, approved the final draft.
- Yong Cao performed the experiments, approved the final draft.
- Xueqin Song performed the experiments, approved the final draft.
- Xiaoyan Wang performed the experiments, contributed reagents/materials/analysis tools, approved the final draft.
- Yan Li performed the experiments, approved the final draft.
- Minglan Yu performed the experiments, approved the final draft.
- Mingying Li performed the experiments, approved the final draft.
- Xu Liu performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables, approved the final draft.
- Fang Huang performed the experiments, approved the final draft.
- Feng Chen conceived and designed the experiments, approved the final draft.
- Haisu Wan conceived and designed the experiments, authored or reviewed drafts of the paper, approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

The Ethics Committee of the Affiliated Hospital of Southwest Medical University provided approval (k2018002-r) to carry out the study within its facilities.

Data Availability

The following information was supplied regarding data availability:

GEO accession [GSE121976](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE121976).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.6607#supplemental-information>.

REFERENCES

- Abe M, Hamada J, Takahashi O, Takahashi Y, Tada M, Miyamoto M, Morikawa T, Kondo S, Moriuchi T. 2006. Disordered expression of HOX genes in human non-small cell lung cancer. *Oncology Reports* 15:797–802 DOI [10.3892/or.15.4.797](https://doi.org/10.3892/or.15.4.797).
- Anders S, Pyl PT, Huber W. 2015. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31(2):166–169 DOI [10.1093/bioinformatics/btu638](https://doi.org/10.1093/bioinformatics/btu638).
- Cai HX, Zhu ZQ, Sun XM, Li ZR, Chen YB, Dong GK. 2015. Gene expression profile of human esophageal squamous carcinoma cell line TE-1. *International Journal of Clinical and Experimental Medicine* 8(8):14268–14276.
- Cantile M, Franco R, Schiavo G, Procino A, Cindolo L, Botti G, Cillo C. 2011. The HOX genes network in uro-genital cancers: mechanisms and potential therapeutic implications. *Current Medicinal Chemistry* 18(32):4872–4884 DOI [10.2174/092986711797535182](https://doi.org/10.2174/092986711797535182).
- Chang SL, Chan TC, Chen TJ, Lee SW, Lin LC, Win KT. 2017. HOXC6 overexpression is associated with Ki-67 expression and poor survival in NPC patients. *Journal of Cancer* 8(9):1647–1654 DOI [10.7150/jca.18893](https://doi.org/10.7150/jca.18893).
- Chen Z, Li Z, Li W, Zong Y, Zhu Y, Miao Y, Xu Z. 2015. SATB1 promotes pancreatic cancer growth and invasion depending on MYC activation. *Digestive Diseases and Sciences* 60(11):3304–3317 DOI [10.1007/s10620-015-3759-9](https://doi.org/10.1007/s10620-015-3759-9).
- Chen JL, Li J, Kiriluk KJ, Rosen AM, Paner GP, Antic T, Lussier YA, Vander Griend DJ. 2012b. Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. *Clinical Cancer Research* 18(16):4291–4302 DOI [10.1158/1078-0432.CCR-12-0373](https://doi.org/10.1158/1078-0432.CCR-12-0373).
- Chen J, Wang M, Xi B, Xue J, He D, Zhang J, Zhao Y. 2012a. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. *PLOS ONE* 7(8):e42413 DOI [10.1371/journal.pone.0042413](https://doi.org/10.1371/journal.pone.0042413).
- Chen SW, Zhang Q, Xu ZF, Wang HP, Shi Y, Xu F, Zhang WJ, Wang P, Li Y. 2016. HOXC6 promotes gastric cancer cell invasion by upregulating the expression of MMP9. *Molecular Medicine Reports* 14(4):3261–3268 DOI [10.3892/mmr.2016.5640](https://doi.org/10.3892/mmr.2016.5640).
- Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. 2010. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. *Cancer Research* 70(2):453–462 DOI [10.1158/0008-5472.CAN-09-2189](https://doi.org/10.1158/0008-5472.CAN-09-2189).
- Du YB, Dong B, Shen LY, Yan WP, Dai L, Xiong HC, Liang Z, Kang XZ, Qin B, Chen KN. 2014. The survival predictive significance of HOXC6 and HOXC8 in esophageal squamous cell carcinoma. *Journal of Surgical Research* 188(2):442–450 DOI [10.1016/j.jss.2014.01.017](https://doi.org/10.1016/j.jss.2014.01.017).
- Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. 2008. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. *Nature* 452(7184):187–193 DOI [10.1038/nature06781](https://doi.org/10.1038/nature06781).

- Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. *Cell* **144**(5):646–674 DOI [10.1016/j.cell.2011.02.013](https://doi.org/10.1016/j.cell.2011.02.013).
- Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa A, Searle S, Barnes I, Bignell A, Boychenko V, Hunt T, Kay M, Mukherjee G, Rajan J, Despacio-Reyes G, Saunders G, Steward C, Harte R, Lin M, Howald C, Tanzer A, Derrien T, Chrast J, Walters N, Balasubramanian S, Pei B, Tress M, Rodriguez JM, Ezkurdia I, Van Baren J, Brent M, Haussler D, Kellis M, Valencia A, Reymond A, Gerstein M, Guigo R, Hubbard TJ. 2012. GENCODE: the reference human genome annotation for The ENCODE Project. *Genome Research* **22**(9):1760–1774 DOI [10.1101/gr.135350.111](https://doi.org/10.1101/gr.135350.111).
- Hu ZY, Liu YP, Xie LY, Wang XY, Yang F, Chen SY, Li ZG. 2016. AKAP-9 promotes colorectal cancer development by regulating Cdc42 interacting protein 4. *Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease* **1862**(6):1172–1181 DOI [10.1016/j.bbadis.2016.03.012](https://doi.org/10.1016/j.bbadis.2016.03.012).
- Hui P, Xu X, Xu L, Hui G, Wu S, Lan Q. 2015. Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis. *International Journal of Clinical and Experimental Pathology* **8**(4):3556–3567.
- Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros JM, Levi D, Gaetani P, Tunici P, Finocchiaro G, Baena RR, Capra M, Helin K. 2009. A role for the transcription factor HEY1 in glioblastoma. *Journal of Cellular and Molecular Medicine* **13**(1):136–146 DOI [10.1111/j.1582-4934.2008.00307.x](https://doi.org/10.1111/j.1582-4934.2008.00307.x).
- Hur H, Lee JY, Yun HJ, Park BW, Kim MH. 2014. Analysis of HOX gene expression patterns in human breast cancer. *Molecular Biotechnology* **56**(1):64–71 DOI [10.1007/s12033-013-9682-4](https://doi.org/10.1007/s12033-013-9682-4).
- Hussain I, Bhan A, Ansari KI, Deb P, Bobzean SA, Perrotti LI, Mandal SS. 2015. Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer. *Biochimica et Biophysica Acta (BBA)—Gene Regulatory Mechanisms* **1849**(6):697–708 DOI [10.1016/j.bbagrm.2015.02.003](https://doi.org/10.1016/j.bbagrm.2015.02.003).
- Ji M, Feng Q, He G, Yang L, Tang W, Lao X, Zhu D, Lin Q, Xu P, Wei Y, Xu J. 2016. Silencing homeobox C6 inhibits colorectal cancer cell proliferation. *Oncotarget* **7**(20):29216–29227 DOI [10.18632/oncotarget.8703](https://doi.org/10.18632/oncotarget.8703).
- Kanai M, Hamada J, Takada M, Asano T, Murakawa K, Takahashi Y, Murai T, Tada M, Miyamoto M, Kondo S, Moriuchi T. 2010. Aberrant expressions of HOX genes in colorectal and hepatocellular carcinomas. *Oncology Reports* **23**:843–851.
- Kashyap MK, Marimuthu A, Kishore CJ, Peri S, Keerthikumar S, Prasad TSK, Mahmood R, Rao S, Ranganathan P, Sanjeeviah RC, Vijayakumar M, Kumar KV, Montgomery EA, Kumar RV, Pandey A. 2009. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. *Cancer Biology & Therapy* **8**(1):36–46 DOI [10.4161/cbt.8.1.7090](https://doi.org/10.4161/cbt.8.1.7090).
- Kim D, Langmead B, Salzberg SL. 2015. HISAT: a fast spliced aligner with low memory requirements. *Nature Methods* **12**(4):357–360 DOI [10.1038/nmeth.3317](https://doi.org/10.1038/nmeth.3317).
- Ladam F, Sagerstrom CG. 2014. Hox regulation of transcription: more complex(es). *Developmental Dynamics* **243**(1):4–15 DOI [10.1002/dvdy.23997](https://doi.org/10.1002/dvdy.23997).
- Lang F, Perrotti N, Stourmaras C. 2010. Colorectal carcinoma cells—regulation of survival and growth by SGK1. *International Journal of Biochemistry & Cell Biology* **42**(10):1571–1575 DOI [10.1016/j.biocel.2010.05.016](https://doi.org/10.1016/j.biocel.2010.05.016).
- Liang X, Lan C, Jiao G, Fu W, Long X, An Y, Wang K, Zhou J, Chen T, Li Y, Xu J, Huang Q, Xu B, Xiao J. 2017. Therapeutic inhibition of SGK1 suppresses colorectal cancer. *Experimental & Molecular Medicine* **49**(11):e399 DOI [10.1038/emm.2017.184](https://doi.org/10.1038/emm.2017.184).

- Liao WT, Jiang D, Yuan J, Cui YM, Shi XW, Chen CM, Bian XW, Deng YJ, Ding YQ. 2011. HOXB7 as a prognostic factor and mediator of colorectal cancer progression. *Clinical Cancer Research* 17(11):3569–3578 DOI 10.1158/1078-0432.CCR-10-2533.
- Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biology* 15(12):550 DOI 10.1186/s13059-014-0550-8.
- Luo CL, Liu YQ, Wang P, Song CH, Wang KJ, Dai LP, Zhang JY, Ye H. 2016. The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. *Biomedicine & Pharmacotherapy* 82:595–605 DOI 10.1016/j.biopha.2016.05.029.
- Malik MF, Satherley LK, Davies EL, Ye L, Jiang WG. 2016. Expression of semaphorin 3C in breast cancer and its impact on adhesion and invasion of breast cancer cells. *Anticancer Research* 36(3):1281–1286.
- Man J, Shoemake J, Zhou W, Fang X, Wu Q, Rizzo A, Prayson R, Bao S, Rich JN, Yu JS. 2014. Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation. *Cell Reports* 9(5):1812–1826 DOI 10.1016/j.celrep.2014.10.055.
- Mao L, Yang C, Wang J, Li W, Wen R, Chen J, Zheng J. 2013. SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. *Journal of Translational Medicine* 11(1):111 DOI 10.1186/1479-5876-11-111.
- Moroz A, Delella FK, Lacorte LM, Deffune E, Felisbino SL. 2013. Fibronectin induces MMP2 expression in human prostate cancer cells. *Biochemical and Biophysical Research Communications* 430(4):1319–1321 DOI 10.1016/j.bbrc.2012.12.031.
- Qian P, Zuo Z, Wu Z, Meng X, Li G, Wu Z, Zhang W, Tan S, Pandey V, Yao Y, Wang P, Zhao L, Wang J, Wu Q, Song E, Lobie PE, Yin Z, Zhu T. 2011. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. *Cancer Research* 71(20):6463–6474 DOI 10.1158/0008-5472.CAN-11-1322.
- Ramachandran S, Liu P, Young AN, Yin-Goen Q, Lim SD, Laycock N, Amin MB, Carney JK, Marshall FF, Petros JA, Moreno CS. 2005. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. *Oncogene* 24(1):188–198 DOI 10.1038/sj.onc.1207906.
- Riihila PM, Nissinen LM, Ala-Aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kahari VM. 2014. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. *Journal of Investigative Dermatology* 134(2):498–506 DOI 10.1038/jid.2013.346.
- Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. 2009a. INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. *Journal of Thoracic Oncology* 4(4):455–462 DOI 10.1097/JTO.0b013e31819c791a.
- Seder CW, Hartojo W, Lin L, Silvers AL, Wang Z, Thomas DG, Giordano TJ, Chen G, Chang AC, Orringer MB, Beer DG. 2009b. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. *Neoplasia* 11(4):388–396 DOI 10.1593/neo.81582.
- Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D, Weissenberger J. 2011. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. *Journal of Neuro-Oncology* 101(3):393–403 DOI 10.1007/s11060-010-0273-y.
- Seol HS, Lee SE, Song JS, Rhee JK, Singh SR, Chang S, Jang SJ. 2016. Complement proteins C7 and CFH control the stemness of liver cancer cells via LSF-1. *Cancer Letters* 372(1):24–35 DOI 10.1016/j.canlet.2015.12.005.

- Shaoqiang C, Yue Z, Yang L, Hong Z, Lina Z, Da P, Qingyuan Z. 2013. Expression of HOXD₃ correlates with shorter survival in patients with invasive breast cancer. *Clinical & Experimental Metastasis* 30:155–163 DOI 10.1007/s10585-012-9524-y.
- Sponziello M, Rosignolo F, Celano M, Maggisano V, Pecce V, De Rose RF, Lombardo GE, Durante C, Filetti S, Damante G, Russo D, Bulotta S. 2016. Fibronectin-1 expression is increased in aggressive thyroid cancer and favors the migration and invasion of cancer cells. *Molecular and Cellular Endocrinology* 431:123–132 DOI 10.1016/j.mce.2016.05.007.
- Sui CJ, Xu F, Shen WF, Dai BH, Lu JJ, Zhang MF, Yang JM. 2016. MicroRNA-147 suppresses human hepatocellular carcinoma proliferation migration and chemosensitivity by inhibiting HOXC6. *American Journal of Cancer Research* 6(12):2787–2798.
- Tait DL, Bahrani-Mostafavi Z, Vestal CG, Richardson C, Mostafavi MT. 2015. Downregulation of HOXC6 in serous ovarian cancer. *Cancer Investigation* 33(7):303–311 DOI 10.3109/07357907.2015.1041641.
- Tsuru A, Setoguchi T, Matsunoshita Y, Nagao-Kitamoto H, Nagano S, Yokouchi M, Maeda S, Ishidou Y, Yamamoto T, Komiya S. 2015. Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metalloproteinase 9 expression. *British Journal of Cancer* 112(7):1232–1240 DOI 10.1038/bjc.2015.84.
- Ulasov I, Yi R, Guo D, Sarvaiya P, Cobbs C. 2014. The emerging role of MMP14 in brain tumorigenesis and future therapeutics. *Biochimica et Biophysica Acta (BBA)—Reviews on Cancer* 1846(1):113–120 DOI 10.1016/j.bbcan.2014.03.002.
- Vaz J, Ansari D, Sasor A, Andersson R. 2015. SPARC: a potential prognostic and therapeutic target in pancreatic cancer. *Pancreas* 44(7):1024–1035 DOI 10.1097/MPA.0000000000000409.
- Wang YP, Huang LY, Sun WM, Zhang ZZ, Fang JZ, Wei BF, Wu BH, Han ZG. 2013. Insulin receptor tyrosine kinase substrate activates EGFR/ERK signalling pathway and promotes cell proliferation of hepatocellular carcinoma. *Cancer Letters* 337(1):96–106 DOI 10.1016/j.canlet.2013.05.019.
- Xu X, Zhao Z, Guo S, Li J, Liu S, You Y, Ni B, Wang H, Bie P. 2017. Increased semaphorin 3c expression promotes tumor growth and metastasis in pancreatic ductal adenocarcinoma by activating the ERK1/2 signaling pathway. *Cancer Letters* 397:12–22 DOI 10.1016/j.canlet.2017.03.014.
- Yan T, Lin Z, Jiang J, Lu S, Chen M, Que H, He X, Que G, Mao J, Xiao J, Zheng Q. 2015. MMP14 regulates cell migration and invasion through epithelial-mesenchymal transition in nasopharyngeal carcinoma. *American Journal of Translational Research* 7(5):950–958.
- Yang MH, Hu ZY, Xu C, Xie LY, Wang XY, Chen SY, Li ZG. 2015. MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. *Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease* 1852(1):166–174 DOI 10.1016/j.bbadis.2014.11.013.
- Yin J, Chen G, Liu Y, Liu S, Wang P, Wan Y, Wang X, Zhu J, Gao H. 2010. Downregulation of SPARC expression decreases gastric cancer cellular invasion and survival. *Journal of Experimental & Clinical Cancer Research* 29:59 DOI 10.1186/1756-9966-29-59.
- Yu G, Wang LG, Han Y, He QY. 2012. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS: A Journal of Integrative Biology* 16(5):284–287 DOI 10.1089/omi.2011.0118.
- Yuan G, Regel I, Lian F, Friedrich T, Hitkova I, Hofheinz RD, Strobel P, Langer R, Keller G, Rocken C, Zimmermann W, Schmid RM, Ebert MPA, Burgermeister E. 2013. WNT6 is a

novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. *Oncogene* **32**(3):375–387 DOI [10.1038/onc.2012.40](https://doi.org/10.1038/onc.2012.40).

Zarrabi K, Dufour A, Li J, Kuscu C, Pulkoski-Gross A, Zhi J, Hu Y, Sampson NS, Zucker S, Cao J. 2011. Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration. *Journal of Biological Chemistry* **286**(38):33167–33177 DOI [10.1074/jbc.M111.256644](https://doi.org/10.1074/jbc.M111.256644).

Zhang Y. 2013. Epidemiology of esophageal cancer. *World Journal Gastroenterology* **19**(34):5598–5606 DOI [10.3748/wjg.v19.i34.5598](https://doi.org/10.3748/wjg.v19.i34.5598).

Zhang Q, Jin XS, Yang ZY, Wei M, Liu BY, Gu QL. 2013. Upregulated Hoxc6 expression is associated with poor survival in gastric cancer patients. *Neoplasma* **60**(4):439–445 DOI [10.4149/neo_2013_057](https://doi.org/10.4149/neo_2013_057).

Zhang H, Sun Z, Li Y, Fan D, Jiang H. 2017. MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells. *Biomedicine & Pharmacotherapy* **88**:285–292 DOI [10.1016/j.biopha.2017.01.023](https://doi.org/10.1016/j.biopha.2017.01.023).

Zheng XL, Yu HG. 2018. Wnt6 contributes tumorigenesis and development of colon cancer via its effects on cell proliferation, apoptosis, cell-cycle and migration. *Oncology Letters* **16**:1163–1172 DOI [10.3892/ol.2018.8729](https://doi.org/10.3892/ol.2018.8729).